As Biohaven reported its fourth quarter and full-year 2021 earnings to investors, the biotech unveiled two new deals — a licensing deal with a Big Pharma and an acquisition of a smaller company.
Biohaven is in-licensing a Phase III-ready compound for spinal muscular atrophy from Bristol Myers Squibb, the companies...
